Literature DB >> 2594067

Specificity pockets for the side chains of peptide antigens in HLA-Aw68.

T P Garrett1, M A Saper, P J Bjorkman, J L Strominger, D C Wiley.   

Abstract

We have determined the structure of a second human histocompatibility glycoprotein, HLA-Aw68, by X-ray crystallography and refined it to a resolution of 2.6 A. Overall, the structure is extremely similar to that of HLA-A2 (refs 1, 2; and M.A.S. et al., manuscript in preparation), although the 11 amino-acid substitutions at polymorphic residues in the antigen-binding cleft alter the detailed shape and electrostatic charge of that site. A prominent negatively charged pocket within the cleft extends underneath the alpha-helix of the alpha 1-domain, providing a potential subsite for recognizing a positively charged side chain or peptide N terminus. Uninterpreted electron density, presumably representing an unknown 'antigen(s)', which seems to be different from that seen in the HLA-A2 structure, occupies the cleft and extends into the negatively charged pocket in HLA-Aw68. The structures of HLA-Aw68 and HLA-A2 demonstrate how polymorphism creates and alters subsites (pockets) positioned to bind peptide side chains, thereby suggesting the structural basis for allelic specificity in foreign antigen binding.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2594067     DOI: 10.1038/342692a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  153 in total

Review 1.  HLA-DM and the MHC class II antigen presentation pathway.

Authors:  P E Jensen; D A Weber; W P Thayer; X Chen; C T Dao
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses.

Authors:  F Micheletti; M Bazzaro; A Canella; M Marastoni; S Traniello; R Gavioli
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

3.  Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection.

Authors:  G W Nelson; R Kaslow; D L Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

4.  A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor.

Authors:  Vasso Apostolopoulos; Elizabeth Yuriev; Paul A Ramsland; Jodie Halton; Carla Osinski; Wenjun Li; Magdalena Plebanski; Hans Paulsen; Ian F C McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

5.  Alternate interactions define the binding of peptides to the MHC molecule IA(b).

Authors:  Xinqi Liu; Shaodong Dai; Frances Crawford; Rachel Fruge; Philippa Marrack; John Kappler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

6.  The multi-locus H-2Dw16 region has an organization distinct from the Dd region.

Authors:  U Tummuru; M K Zubairu; D R Lee
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

Review 7.  Molecular mechanisms involved in the etiology and pathogenesis of autoimmune diseases.

Authors:  M Trucco
Journal:  Clin Investig       Date:  1992-09

Review 8.  Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs)--a novel approach to the protection of humans.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1994-09       Impact factor: 2.332

Review 9.  A cold-blooded view of adaptive immunity.

Authors:  Martin F Flajnik
Journal:  Nat Rev Immunol       Date:  2018-07       Impact factor: 53.106

10.  Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein.

Authors:  A Bertoletti; F V Chisari; A Penna; S Guilhot; L Galati; G Missale; P Fowler; H J Schlicht; A Vitiello; R C Chesnut
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.